Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 20,300 shares, a growth of 18.0% from the February 13th total of 17,200 shares. Based on an average trading volume of 30,300 shares, the short-interest ratio is currently 0.7 days. Approximately 0.6% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Assembly Biosciences Stock Performance

Shares of NASDAQ:ASMB opened at $10.69 on Friday. The firm has a fifty day moving average price of $13.00 and a 200 day moving average price of $15.18. Assembly Biosciences has a fifty-two week low of $10.27 and a fifty-two week high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.12) by $0.55. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. Research analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael Houghton bought 3,202 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the acquisition, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASMB. JPMorgan Chase & Co. boosted its holdings in shares of Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 3,442 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in Assembly Biosciences during the 4th quarter worth approximately $180,000. Marshall Wace LLP raised its position in Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 2,098 shares during the last quarter. FMR LLC raised its position in Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the last quarter. Finally, Man Group plc purchased a new position in Assembly Biosciences during the 4th quarter worth approximately $309,000. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.